DTP Vaccines Market Report 2026

The dtp vaccines market size has grown strongly in recent years. It will grow from $5.47 billion in 2025 to $5.79 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of diphtheria, tetanus, and pertussis, growing pediatric population, rising government immunization programs, limited vaccine accessibility in rural areas, increasing awareness of childhood vaccination benefits.

The dtp vaccines market size is expected to see strong growth in the next few years. It will grow to $7.63 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to development of next-generation combination vaccines, expansion of school and community vaccination programs, integration of digital vaccination tracking systems, increasing public-private partnerships for immunization, rising global funding and support for child health initiatives. Major trends in the forecast period include expansion of pediatric immunization programs and campaigns, increasing awareness of dtp vaccination benefits among parents, growth in combination vaccine adoption for convenience and compliance, integration of vaccination tracking and reminder systems, rising government initiatives for maternal and child immunization.

The escalating healthcare expenditure is poised to accelerate the DTP vaccine market ahead. Healthcare expenditure covers the aggregate spending on medical goods and services, encompassing equipment, hospital care, doctor visits, medications, and public health efforts. This funding creates fertile ground for advancing, producing, distributing, and deploying DTP vaccines effectively. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported UK healthcare spending hit roughly $379 billion (£292 billion) in 2023. This reflected a 5.6% nominal jump from 2022, a sharp rebound from the prior year's 0.9% uptick. Therefore, the increasing healthcare expenditure is driving the growth of the DTP vaccine market.

Prominent companies in the DTP vaccines market are pioneering novel approaches like combination and next-generation vaccine initiatives to broaden immunization reach, streamline dosing, and strengthen defenses against diphtheria, tetanus, and pertussis in kids and at-risk groups. Combination vaccines merge multiple antigens into one shot, cutting injection counts, boosting adherence, and matching single-antigen potency. For instance, in December 2023, Gavi, the Vaccine Alliance, a Switzerland-based public-private health partnership, broadened its lineup with enhanced DTP-inclusive vaccines within immunization drives. These shield against diphtheria, tetanus, and pertussis - often paired with hepatitis B or Haemophilus influenzae type b - sparking potent immune reactions across pathogens; highlights encompass fewer doses, unified antigen delivery, and integration for low- and middle-income nations; uses span routine child shots, outbreak blocks, and boosters; perks feature higher coverage, easier logistics, and better guard against preventable illnesses.

In May 2025, PT Bio Farma (Persero), an Indonesia-based biopharmaceutical company, teamed with Bionet Asia Ltd. to widen Tdap vaccine access across ASEAN. This alliance merges PT Bio Farma's production strengths with Bionet Asia's networks and market entry savvy to lift regional immunization rates, ensuring ample, affordable, on-time Tdap supplies for public health demands. Bionet Asia Ltd. is a Singapore-based healthcare company that specializes in providing DTP-containing vaccines, including a Tdap (Tetanus, Diphtheria, and acellular Pertussis) vaccine, as well as a pentavalent DTP-Hib-HBV vaccine.

Major companies operating in the dtp vaccines market are GlaxoSmithKline, Sanofi, Merck & Co Inc, Meiji Holdings Co. Ltd, Shenzhen Kangtai Biological Products, AJ Vaccines, PT Bio Farma, Bio Med, Sinergium Biotech SA, Teva Pharmaceutical Industries Ltd F. Hoffmann-La Roche AG, Boehringer Ingelheim, CanSino Biologics, Gilead Sciences, Panacea Biotec Ltd, Fiocruz, Johnson & Johnson, Walvax biotechnology, National Administration of Laboratories and Institutes of Health (ANLIS), Zentiva, Afrigen Biologics & Vaccines.

North America was the largest region in the DTP vaccines market in 2025. The regions covered in the dtp vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dtp vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the DTP vaccines market by increasing costs for imported vaccine components, syringes, and cold-chain logistics equipment. Hospital vaccination centers and clinics in regions like North America and Europe that rely heavily on imports are most affected. This has led to higher operational costs and potential delays in vaccine distribution. On the positive side, tariffs have encouraged local vaccine manufacturing, investment in domestic cold-chain infrastructure, and development of cost-effective vaccine solutions.

The dtp vaccines market research report is one of a series of new reports that provides dtp vaccines market statistics, including dtp vaccines industry global market size, regional shares, competitors with a dtp vaccines market share, detailed dtp vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the dtp vaccines industry. This dtp vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diphtheria, Tetanus, Pertussis (DTP) vaccines are combination vaccines administered intramuscularly to protect children under 7 years old from diphtheria, tetanus, and whooping cough. They help children develop immunity against these three potentially fatal bacterial diseases.

The main types of DTP vaccine products are DTaP, TD, and Tdap. DTaP vaccines protect children under 7 against diphtheria, tetanus, and pertussis. These vaccines address diseases such as diphtheria, pertussis, and tetanus and are used across hospitals, clinics, and vaccination centers.

The DTP vaccine market consists of sales of Daptacel, Infanrix, Kinrix, Paediarix, Pentacel, Quadracel, and Vaxelis vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.